Abstract
BackgroundHead and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates.MethodsThe systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95% confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger’s bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient.DiscussionThere is a lack of highly sensitive and specific biomarkers for estimating the HNC patients’ prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression.Systematic review registrationThis review protocol was registered on PROSPERO and assigned the registration number CRD42017077411.
Highlights
Head and neck cancers form a significant share of all cancer incidences worldwide
Systematic review registration: This review protocol was registered on PROSPERO and assigned the registration number CRD42017077411
Previous reports have highlighted the association between miRNA expression and Head and neck cancer (HNC) disease prognosis
Summary
Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. Head and neck cancer (HNC) is the sixth leading cancer worldwide, with an annual incidence rate of more than 550,000 cases with around 300,000 deaths each year [1]. It has strong associations with specific environmental and lifestyle risk factors, such as tobacco and alcohol consumption, Epstein-Barr virus (EBV) and human papillomavirus (HPV) infection [2]. Prognosis of HNC patients in post-treatment condition, is primarily the result of subjective analysis during treatment by assessment of histological grade, the pattern of tumour invasion, the proximity of carcinoma to resection margins and the presence of extra-nodal spread [5]. The deregulated miRNA expression profile found in the cancerous state of HNC has been suggested as an avenue for cancer screening, diagnosis and prognosis [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
